Immunogenicity and toxicity of AAV gene therapy.

Ertl HCJ. · 2022

Read Immunogenicity and toxicity of AAV gene therapy. by Ertl HCJ. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9411526.txt.

Introduction

Ertl reviews the immune risks that limit AAV gene therapy. Vectors built from adeno-associated virus have cured diseases such as hemophilia A and B. Yet immune responses to the virus shell or the new gene product still block progress. High vector doses bring the worst harm.

The review covers innate and adaptive responses in turn. T cells can kill corrected cells, while B cells make antibodies that bar repeat dosing. Complement activation has caused grave adverse events in trials. Liver damage and dorsal root ganglia toxicity are also covered. Drugs that blunt T cells help some patients but fail others. Ertl argues for stronger vectors that allow lower doses. Smaller repeat doses with B cell control are another path worth testing.

Catalog record

CREATORErtl HCJ.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE51 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9411526

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Immunogenicity and toxicity of AAV gene therapy By Hildegund C J Ertl Published in: Frontiers in Immunology DOI: 10.3389/fimmu.2022.975803 ABSTRACT Abstract Gene transfer using adeno-associated viral (AAV) vectors has made tremendous progress in the last decade and has achieved cures of debilitating diseases such as hemophilia A and B. Nevertheless, progress is still being hampered by immune responses against the AAV capsid antigens or the transgene products. Immunosuppression designed to blunt T cell responses has shown success in some patients but failed in others especially if they received very high AAV vectors doses. Although it was initially thought that AAV vectors induce only marginal innate responses below the threshold of systemic symptoms recent trials have shown that complement activation can results in serious adverse events. Dorsal root ganglia toxicity has also been identified as a complication of high vector doses as has severe hepatotoxicity. Most of the critical complications occur in patients who are treated with very high vector doses indicating that the use of more efficient AAV vectors to allow for dose sparing or giving smaller doses repeatedly, the latter in conjunction with antibody or B cell depleting measures, should be explored. Keywords: AAV, T cell responses, B cell responses, innate immune responses, serious adverse events INTRODUCTION Gene transfer using vectors based on adeno-associated viruses (AAV) has achieved lessening of symptoms or even cures of diseases caused by single gene defects such as Leber’s congenital amaurosis, a congenital form of blindness (1), or hemophilia B due to loss-of-function mutations within the gene encoding coagulation factor 9 (2). Although AAV vectors are poorly immunogenic and persist in mice, dogs, and nonhuman primates for many years (3–5), humans injected with large doses mount T and B cell responses against the AAV capsid or even the transgene product. T cells can lead to rejection of transduced cells (6, 7) while B cells if they produce AAV neutralizing antibodies prevent successful reapplication of the vector (8). Even worse if antibodies neutralize a soluble transgene product, they may interfere with traditional protein therapies (9). Immune mediated rejection of AAV vector transduced cells can in part be prevented by immunosuppressants given during or shortly after gene transfer (2). Immunosuppressive drugs have improved the outcome of AAV-mediated gene transfer, but some patients fail to respond and still reject the AAV-transduced cells (10–12) while others do not need the drugs but receive them as it still impossible to predict which patients will or will not mount destructive immune responses. Although we have gained over the last two decades a better understanding of innate and adaptive immune responses to natural infections with AAV or AAV vector-mediated gene transfer using different serotypes applied at various doses to different organs some basic questions remain unanswered. This manuscript reviews the different types of immune responses that are elicited by AAVs and how they translate into lack of efficacy or even worse toxicity ( Figure 1 ). [Figure: Immune responses and toxicity to AAV vectors. The graph shows the different type of immune responses that are elicited upon injection of AAV vectors. Toxicities are underlined and listed next to the components of the immune responses that contribute or may (?)contribute to the adverse events. The following abbreviations are used within the figure: CpG, unmethylated CpG motifs; C1 and C3, complement factors 1 or 3; DCs, dendritic cells; DRG, Dorsal root ganglia, dsRNA, double stranded RNA; MAC, membrane attack complex; MHC, major histocompatibility complex; NK cells, natural killer cells, TMA, thrombotic microangiopathy,? – remains to be tested in more detail.] BASIC BIOLOGY OF AAVS AND AAV VECTORS AAVs are dependoviruses that naturally infect primates and other species where they can replicate with the assistance of a helper virus such as an adenovirus. As a genus they have a wide host cell range for both resting and dividing cells although different serotypes of AAVs or AAV vectors have a more restricted tropism; for example, in humans AAV1 vectors have high tropism for muscle while AAV2 vectors readily infects lung and brain cells (13). Tropism may differ between species: AAV8 vectors more efficiently infect mouse than human hepatocytes (14). AAV infections are asymptomatic, and the virus persist for the lifetime of an individual. Nevertheless, AAVs are immunogenic as they stimulate detectable B and T cell responses (15). As induction of long-lived adaptive immunity depends on antigen-presenting cells that require prior maturation driven by inflammatory signals AAV infections must be able to trigger innate immune responses that upon a natural infection may in part be driven by the helper virus. AAVs carry a single stranded DNA genome with two open reading frames (ORFs) encoding regulatory proteins as well as the capsid antigens. The genome is flanked by invert terminal repeat (ITR) sequences. In AAV vectors the two ORFs are deleted and replaced with an expression cassette for a therapeutic protein or RNA; during viral production the deleted sequences as well as essential sequences from a helper virus are provided in trans. Upon injection antigens from the capsids of AAV vectors are present in the inoculum but they, unlike the transgene product, are not actively produced by the transduced cells. This is turn limits the duration of presentation of capsid antigens to the immune system till the proteins are degraded, which according to clinical trial results may take months (16). IMMUNOLOGY 101 AS IT PERTAINS TO AAVS AND AAV VECTORS Innate responses Viruses or viral vectors carry either within their antigens or their genome pathogen-associated molecular patters (PAMP), which are absent in mammals and therefore recognized as threats by so-called pathogen recognition receptors (PRR), which are located on the cell surface, within endosomes or the cytosol (17). Expression of certain types of PRRs such as Toll-like receptors (TLR) is commonly cell-type specific; for example, TLR2 is expressed by macrophages but not dendritic cells while TLR3 has the opposite expression pattern (18). Binding of a PAMP to a PRR initiates a signaling cascade that ultimately results in activation of transcription factors such as nuclear factor kappa B (NF-kB), activator protein 1 (AP-1), interferon regulatory factors (IRF)-3 and -7 (19). This initiates production of inflammatory mediators such as cytokines and chemokines, maturation of dendritic cells into professional antigen presenting cells and activation of other cells of the innate immune system such as natural killer cells, macrophages and neutrophiles. Viruses can also elicit inflammatory responses by initiating an unfolded protein response that is typically triggered as a reaction to endoplasmic reticulum (ER) stress. AAV vectors expressing for example the coagulation factor VIII trigger an ER stress response due to overexpression of this protein; ER stress in turn is likely to promote activation of AAV- or FVIII-specific immune responses (20). In most cases innate immune responses are non-antigen-specific, their activation is short-lived, and they lack ‘memory’ so that a 2nd exposure to the same pathogen elicits very similar responses. Complement, which is part of the innate immune system but relies in some respects on effector molecules of the adaptive immune system provides a crucial defense mechanism against viruses. It can kill or neutralize viruses directly, it can aggregate viruses, promote their phagocytosis by leukocytes, and in concert with virus-specific antibodies kill infected cells thereby stopping production of new viral progeny (21).

Read the complete text